Redeye provides a comment on Xspray following yesterday's press release announcing a delay in the resubmission of its NDA to March/April 2025, compared to the previous timeline of Q4 2024. We adjust our valuation accordingly.
ANNONS
Redeye provides a comment on Xspray following yesterday's press release announcing a delay in the resubmission of its NDA to March/April 2025, compared to the previous timeline of Q4 2024. We adjust our valuation accordingly.